____ _ _ _ _ _ _ _ _ _ _ _ _ _ n_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Epsilon

摘要

The present invention provides a recombinant human pre-N_4-sulfatase alpha-kappa__gamma alpha__alpha___with high purity, high bioactivity, and mu_______96 Cognitive and corresponding methods of pharmaceutical preparations, including recombinant human N-terminal pre-4-sulfatase and alpha-kappa epsilon_lambda_gamma alpha lambda__alpha__high ;.The present invention also provides a method for the treatment of diseases induced by human__lambda____less than 4 Nalpha_______ The method of MPS VI, for example, produces and purify the recombinant enzyme to form a high purity prefix.